Get Updates
Get Updates
Menu

YU know them.

They’re the Presbyopians.

Now YU can transform their near vision with YUVEZZI.

Yuvezzi now available Three actor portrayals of presbyopia patients demonstrating different coping mechanisms for addressing presbyopia

A new dual-agent treatment for managing presbyopia

YUVEZZI combines 2 active ingredients, carbachol and brimonidine tartrate, that work together to deliver consistent and durable pupil modulation1

A less-fuss way to manage presbyopia

  • Significantly more patients achieved ≥ 3-line gain in BUCNVA without ≥ 1-line loss in BUCDVA with YUVEZZI than with vehicle or monotherapies1*

  • YUVEZZI achieves miosis from 30 minutes up to 10 hours with one drop once a day1

  • 6x greater improvement in reading speed with YUVEZZI vs vehicle2†

  • Proven long-term safety over 12 months with no observed retinal detachments² 

  • Patients taking YUVEZZI reported less hyperemia (2.8%) than carbachol alone (10.7%)² 

Woman with presbyopia reading without glasses

YUVEZZI is available direct through PHILRx or retail pharmacies Patients can save more with PHILRx

PHIL Rx and YUVEZZI Cost Savings

$79

30 single-use vials 

$198

90 single-use vials
($39 savings)

The exclusive discounted price for a 90-day supply is available only through PHILRx.

GoodRx and YUVEZZI price discounts
 
 
Pricing may vary across retail pharmacies, so patients can also 
visit GoodRx.com/YUVEZZI to download a savings coupon.

*The efficacy of YUVEZZI was evaluated in 618 patients (aged 45 to 80) with presbyopia in 2 Phase 3 randomized double-masked controlled studies.
Primary endpoint at Hour 1: gain from baseline of >3 lines (15 letters) in binocular uncorrected near visual acuity (BUCNVA) without a loss of >1 line (5 letters) in binocular uncorrected distance visual acuity (BUCDVA).
†Compared to pre-baseline dose. Measured at Day 90.

Sign up to stay informed about ongoing YUVEZZI updates

Loading form…